Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$10.46 USD
-0.03 (-0.29%)
Updated Oct 28, 2025 04:00 PM ET
After-Market: $10.46 0.00 (0.00%) 5:20 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DVAX 10.46 -0.03(-0.29%)
Will DVAX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for DVAX based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for DVAX
Amgen (AMGN) Moves 3.5% Higher: Will This Strength Last?
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
DVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
Exelixis (EXEL) Beats Q2 Earnings Estimates
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
Other News for DVAX
Is DVAX set to rally? Stochastic Reached Overbought shows up after rising 1.06%
Dynavax Technologies Advances in Pneumonic Plague Vaccine Study
DVAX forms Bollinger Band Squeeze on October 24
DVAX forms 50 Day Moving Average Support on October 23
50 Day Moving Average Support appears for DVAX after 0.3% move